(Q36517701)

English

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)

scientific article published on 19 February 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2) (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hisashi Yamanaka

11

object named as

Hisashi Yamanaka

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Kazuyoshi Saito

4

object named as

Kazuyoshi Saito

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

author name string

Yoshiya Tanaka

1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Tsutomu Takeuchi

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Eisuke Inoue

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Naoya Sekiguchi

5

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Eri Sato

6

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Masao Nawata

7

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Hideto Kameda

8

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Shigeru Iwata

9

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Kouichi Amano

10

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

publication date

19 February 2008

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Modern Rheumatology

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

18

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

146-152

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

New therapies for treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2279153

30 September 2017

Proposed [corrected] Japanese guidelines for the use of infliximab for rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2279153

30 September 2017

Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2279153

30 September 2017

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2279153

30 September 2017

Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2279153

30 September 2017

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with c

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2279153

30 September 2017

Treatment continuation in patients receiving biological agents or conventional DMARD therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2279153

30 September 2017

Evolving concepts of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2279153

30 September 2017

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2279153

30 September 2017

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2279153

30 September 2017

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2279153

21 September 2018

Guidelines for the management of rheumatoid arthritis: 2002 Update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2279153

21 September 2018

Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2FS10165-008-0026-3

21 January 2018

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2279153

4 December 2018

Efficacy and safety of the anti-TNF biologic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/18283523

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18283523

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3109/S10165-008-0026-3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36517701&oldid=1873552228"